RXIM002 / RiboX Therapeutics - LARVOL DELTA

First Clinical Proof of Concept of Intravenous RXIM002, a Targeted Lipid Nanoparticle Circular RNA Therapy, for In Vivo Anti-CD19 Chimeric Antigen Receptor T-Cell Generation in Refractory Systemic Lupus Erythematosus (ACR Convergence 2026) - No abstract available

CAR T-Cell Therapy • Circular RNA • Lipid Nanoparticle • Preclinical • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Subcutaneous RXIM002, a Targeted Lipid Nanoparticle Circular RNA Therapy, for In Vivo Anti-CD19 Chimeric Antigen Receptor T-Cell Generation in Effector Memory T cells and Terminally Differentiated Effector T cells for Treatment of Refractory Systemic Lupus Erythematosus (ACR Convergence 2026) - P1 | "This is the first clinical demonstration of a subcutaneously administered in vivo CAR-T and the first SC tLNP-circRNA platform generating functional CAR-T in patients. SC RXIM002 produced rapid, durable CAR-TEM/TEMRA expression, deep B‑cell depletion, and early clinical responses in refractory SLE with manageable safety. These findings support further development of SC RXIM002, potentially enabling outpatient and community‑based administration."

CAR T-Cell Therapy • Circular RNA • IO biomarker • Lipid Nanoparticle • Preclinical • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • CD7 • CD8 • IFNA1 • IFNG • IL10 • IL2 • IL6 • TNFA

POPULUS-1: Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: RiboX Therapeutics Ltd.

New P1 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. (The Manila Times) - "Prior to the IND submission, RXIM002 was evaluated in investigator-initiated trials (IITs) in China in autoimmune disease patients. Follow-up of these patients are currently ongoing, with some patients exceeding six months. RiboX submitted complete IIT data as part of the IND package to the FDA, encompassing safety and early efficacy results from all treated patients."

IND • New P1 trial • Immunology • Thrombocytopenia

Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: Ruijin Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology